Many specific leukemia subtypes have been identified by characteristic and reproducible phenotypic features detected mainly by cytomorphology and immunophenotyping. Further research then led to unraveling recurring cytogenetic and molecular genetic aberrations forming the pathogenetic basis of the respective entities as exemplified by chronic myelogenous leukemia. 1, 2 We here report on 20 cases with acute myeloid leukemia (AML) with limited differentiation as identified by their specific immunophenotype. All of these cases were shown to carry an NPM1 type A mutation.
Out of a nonselected cohort of 1094 AML at diagnosis we detected 20 cases that could be identified based primarily on their specific and unusual immunophenotype comprising 
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FLT3-LM
FLT3-TKD
MLL-PTD
Abbreviations: MPO, myeloperoxidase (immunophenotyping); n.d. ¼ not done; n.r. ¼ no result; POX, myeloperoxidase (cytochemistry); SSC, side scatter signal. + indicates strong antigen expression/presence of mutation; ((+)) weak expression; (+) dim expression; À no antigen expression/mutation not present.
Letters to the Editor a strong expression of myeloperoxidase (MPO) and CD33 and a lack of expression of nearly all other myelomonocytic antigens which are frequently expressed in other AML cases, that is, CD13, CD65, CD15 and CD14 (Table 1) . Furthermore, neither the progenitor cell markers CD34 and CD133 nor HLA-DR were expressed in any of these cases. All cases also displayed a weak side-scatter signal resembling the pattern observed in AML M3 (Figure 1a) . Furthermore, in 18/20 cases a characteristic very weak expression of CD64 was observed (Figure 1b) . CD117 was dimly expressed in 14 out of the 20 cases ( Figure 1c ). Other markers showing a dim expression in some cases included CD9, CD11b, CD38 and CD56; however, the latter two were strongly expressed in about half of the cases. This immunophenotype thus clearly differs from all other AML subtypes as defined by immunophenotype: (1) AML with minimal differentiation in general shows no or only a dim expression of MPO and in most cases, in addition to other myeloid markers, progenitor cell markers and HLA-DR are expressed; (2) the latter markers are mostly expressed in AML without maturation and AML with maturation, furthermore in these cases myeloid markers are expressed at higher numbers than in the present series; (3) myelomonocytic and monoblastic AML feature a coexpression of a variety of myeloid and monocytic markers and most often express HLA-DR. Interestingly, acute promyelocytic leukemia shares some of the immunophenotypic features with the present series (lack of HLA-DR expression, strong MPO expression) but shows additional ones which were not observed in the presented cohort (unspecific fluorescence signals in negative controls, strong expression of other myeloid markers). Furthermore, although there is a weak side-scatter signal in both the present series and in AML M3, it is stronger in the latter group. 3 The present series thus features a distinct immunophenotype which was not described before.
We therefore evaluated clinical characteristics and other laboratory findings. Patients' age was high and ranged from 60 to 86 years (median 70), the male/female ratio was 7:13. Median WBC count amounted to 108.6 g/l (range 2.0 -420.0). Cytomorphology and cytochemistry (MPO and nonspecific esterase) revealed an AML M1 subtype in the large majority of cases (16/20, 80%) whereas the other cases were classified as AML M2 (n ¼ 3) and AML M4 (n ¼ 1). Cases displayed strong MPO staining (median positivity 90%, range 40-100%), Auer rods or dysplastic features were not present. Cup-like morphology (prominent nuclear invaginations 4 ) was present in 12/18 evaluable cases (range 2-20% of blast cells). Chromosome banding analysis was performed in 17 cases and revealed a normal karyotype in 13 (76%) whereas t(1;14)(p34;q32), del(20)(q11) and i(X)(p10) were present in one case each and no result was obtained in one case due to insufficient sample quality. Most surprisingly, molecular genetic analysis revealed an NPM1 type A mutation in all 20 cases (100%) and an FLT3-ITD in 12/20 (60%) cases. No case showed an FLT3 tyrosine kinase domain mutation or an MLL-PTD. Thus, besides the characteristic immunophenotype the present series features a homogeneous cytomorphology, few cytogenetic aberrations which are not considered subclass defining and, most importantly, a consistently occurring NPM1 type A mutation (Figure 1d) . The frequency of an accompanying FLT3-ITD is in the range published for NPM1 mutated AML, however, the 100% frequency of type A NPM1 mutation is significantly higher than the previously reported frequency of 78.3% (w 2 -test, P ¼ 0.02) in 212 patients with unselected AML and NPM1 mutations. 5 A variety of previously published data reports on non-APL AML with lack of HLA-DR expression. [6] [7] [8] Most cases were AML M1/M2 and a high frequency of FLT3-ITD was observed. However, neither a complete and characteristic immuno- Letters to the Editor phenotype nor a clear-cut genetic background has been observed in these studies. Syampurnawati et al. 9 described cases with AML M1/M2 lacking the expression of HLA-DR in which NPM1 mutations were observed in 69%. Thus, a relation to the molecular genetic aberration, that is NPM1 mutation, was found; however, again the correlation was not complete and no comprehensive immunophenotype was described.
The previously described cup-like morphology has been reported to be associated with NPM1 mutations, 4 with FLT3-ITD and with a lack of HLA-DR expression; 10 however, again no complete correlations were observed.
A variety of reports has been published on AML with NPM1 mutations describing cytomorphologic characteristics (high frequency of AML M4/M5), the lack of recurrent genetic abnormalities, and a high frequency of myelomonocytic immunophenotypes as well as an infrequent expression of CD34 5, 11 which led to 'AML with mutated NPM1' being included as a provisional entity in the 2008 WHO classification of tumors of hematopoietic and lymphoid tissues. 12 The report of the present series adds on these data by providing a subgroup of AML cases with NPM1 type A mutations which display a unique and homogeneous immunophenotype. It should be noted, however, that these cases comprise a subgroup only of all AML with NPM1 type A mutations. Taking into consideration previously described leukemia subtypes, which were identified by homogeneous immunophenotypes correlated with cytomorphologic features and in which disease-defining genetic alteration subsequently were identified, the present data may be considered the basis to suggest the presence of a homogeneous genetic background in these cases. Following the two-hit model of pathogenesis of AML as suggested by Gilliland et al. 13 and considering that only the NPM1 type A mutation was consistently found in the present cases a second consistently present and not yet identified mutation may be postulated. Therefore, the present subgroup of AML with NPM1 type A mutation provides an ideal target for further research on the mechanism of leukemogenesis.
